key: cord-0945480-9qg578zb authors: Malaty, Michael; Kayes, Tahrima; Amarasekera, Anjalee Thanuja; Kodsi, Matthew; MacIntyre, C Raina; Tan, Timothy C. title: Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: a systematic review date: 2020-10-12 journal: Eur J Clin Invest DOI: 10.1111/eci.13428 sha: be7c4d30f56c0d22d33bc7e8d7a6782479bd8fe3 doc_id: 945480 cord_uid: 9qg578zb BACKGROUND: The Coronavirus disease 2019 (COVID‐19) pandemic has affected millions of people worldwide resulting in significant morbidity and mortality. Arrhythmias are prevalent and reportedly, the second most common complication. Several mechanistic pathways are proposed to explain the pro‐arrhythmic effects of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. A number of treatment approaches have been trialled, each with its inherent unique challenges. This rapid systematic review aimed to examine the current incidence and available treatment of arrhythmias in COVID‐19, as well as barriers to implementation. METHODS: Our search of scientific databases identified relevant published studies from 1(st) January 2000 until 1(st) June 2020. We also searched Google Scholar for grey literature. We identified 1729 publications of which 1704 were excluded. RESULTS: The incidence and nature of arrhythmias in the setting of COVID‐19 was poorly documented across studies. The cumulative incidence of arrhythmia across studies of hospitalised patients was 6.9%. Drug‐induced long QT syndrome secondary to antimalarial and antimicrobial therapy was a significant contributor to arrhythmia formation, with an incidence of 14.15%. Torsades de pointes (TdP) and sudden cardiac death (SCD) was reported. Treatment strategies aim to minimise this through risk stratification and regular monitoring of corrected QT interval (QTc). CONCLUSION: Patients with SARS‐CoV‐2 are at an increased risk of arrhythmias. Drug therapy is pro‐arrhythmogenic and may result in TdP and SCD in these patients. Risk assessment and regular QTc monitoring are imperative for safety during the treatment course. Further studies are needed to guide future decision making. The Coronaviridae are a family of spherical single stranded, positive-sense ribonucleic acid (RNA) viruses further categorised into four genera namely alpha-, beta-, gamma-, and delta-coronaviruses. Of the strains infecting humans, alpha-coronaviruses including human coronavirus (HCoV) HL63 and 229E, and beta-coronaviruses including HCoV OC43 and HKU1, result in mild, self-limiting respiratory illnesses accounting for 15-30% of common colds. 1, 2 In contrast, the three-novel beta-coronaviruses -severe acute respiratory syndrome coronavirus (SARS-CoV), middle east respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 -result in severe illness responsible for large outbreaks during the twenty-first century. 1 This article is protected by copyright. All rights reserved Reviews and Meta-analysis (PRISMA) guideline 5 All study designs, if available in the English language, including systematic literature reviews and meta-analysis, narrative reviews, randomised control trials (RCTs), non-RCT or quasi-experimental study designs, cross-sectional cohort studies, case reports and case series were included. Articles were required to report either on incidence or prevalence of cardiac arrhythmias due to coronavirus infection in adults, use of drug therapy in patients with SARS-CoV-2 infection as well as management strategies available to address arrhythmias. We defined LQTS as a corrected QT interval (QTc) ≥ 500 milliseconds (ms) or ∆QTc by ≥ 60ms, as these are patients at greatest risk of TdP. 6 Patients with physiologic sinus tachycardia or inherited arrhythmia syndromes were excluded. Non-peer reviewed studies, editorials, conference article proceedings, theses, studies describing animal models or with alternate definition of LQTS, studies that did not report arrhythmia and published articles before year 2000 were excluded. This article is protected by copyright. All rights reserved An initial limited search of Medline and Google Scholar was undertaken followed by analysis of text words contained in the titles and abstracts, and index terms used to describe identified articles. A second search, using all identified key words and index terms was undertaken across all included databases. Finally, reference lists of identified articles were manually searched for additional relevant studies, using defined inclusion and exclusion criteria (Appendix 4). Two authors (TK and MM), independently carried out initial screening of titles and abstracts, which were independently approved by a third author (MK) for inclusion. Any disagreements were resolved through mutual discussions before finalizing literature summary Tables 1-3 . Non-randomised designs were discussed according to guidelines provided within the Transparent Reporting of Non-randomised Designs (TREND) statement 7 and randomised control designs were discussed according to guidelines provided within the CONSORT statement. 8 The risk of bias within and across the selected studies was assessed independently by two authors (TK and MM) using the Joanna Briggs Institute Critical Appraisal tools 9 for assessing prevalence data, randomised control trials and case reports/series (Appendices 5-7). This process afforded increased methodological rigour and evaluated potential bias and threats to validity (Joanna Briggs Institute 2017 https://reviewersmanual.joannabriggs.org/ ). Both reviewers were trained in use of the appraisal tool prior to this process. This article is protected by copyright. All rights reserved We identified 1598 records after duplicates were removed. 1528 articles were removed on basic screening of title and abstract. 70 full-text articles were then assessed for eligibility, of which 25 records met the inclusion criteria (Appendix 4). Figure 2 demonstrates the study selection flow-chart, the types of studies included and reasons for exclusion. Included studies are summarised in tables 1, 2 and 3. A total of 4911 SARS-CoV-2 cases were extracted for assessment of the incidence of arrhythmias (Table 1) . A total of 961 patients were evaluated to calculate the incidence of long QT syndrome (LQTS) and ventricular arrythmias (VA) due to drug therapy with azithromycin (AZ) and/or hydroxychloroquine (HCQ) or chloroquine (CQ) ( Table 3) . Several case reports were included ( Table 2) to illustrate the range of arrhythmias found secondary to SARS-CoV-2 infection and drug therapy but were not included in the cumulative incidences as establishing causality is difficult. Quality appraisals of included studies are presented in Appendices 5-7. Except for Richardson et al 10 , the underpowered sample sizes across the remaining studies is a potential for bias. Across all studies, the total number of patients analysed was 5872, which is a small representation of the total number of SARS-CoV-2 patients. There was marked non-uniformity within the selected cohorts; 99% of one cohort represented mild disease 11 , whilst in other studies patients with all degrees of severity were included based on unspecified clinical criteria. 12,13 Quantitative markers of severity like viraemia, were not used. 13, 14 In addition, some studies included patients without a baseline electrocardiogram (ECG), whilst in other studies, all patients without a baseline ECG were excluded. 11, 15 These factors limit generalisability to the population. Most studies were retrospective monocentric observational studies, with biases in incomplete data collection and variations in reporting. The method used to diagnose This article is protected by copyright. All rights reserved arrhythmias and to calculate QT interval was not reported in some studies which may lead to reporting bias 10, 12, 15, 19, [26] [27] [28] . Furthermore, the retrospective study design lends itself to selection bias. We note large numbers of patients were initially screened in some studies and only a small population included for analysis. 16, 20 The diagnosis of infection was based on polymerase chain reaction (PCR) testing of samples taken from the upper respiratory tract which could lead to false negative results and therefore result in exclusion of infected patients. 11 Although repeat testing improves accuracy, all studies did not address whether further PCR testing was utilised. 11 In two studies, non-PCR confirmed SARS-CoV-2 cases were included in the final analysis which may cause dilution of results in the event that patients without SARS-CoV-2 infection were included. 21, 22 Drug regimens differed in terms of combination, dosages and duration (Table 3) . Drug levels were not widely measured except by Perinel et al, however, assessment of LQTS was not their primary outcome. 17 Hence it is unclear if QTc measurements were taken at maximum drug levels. 21 Only four of ten studies reported drug-induced LQTS (DI-LQTS) as the main outcome, another potential for reporting bias. 15, [23] [24] [25] In one study, the duration of treatment was not specified. 26 The incidence and nature of arrhythmias amongst patients with SARS-CoV-2 was poorly documented. We retrieved data on arrhythmias in SARS-CoV-2 in only 5 of thirteen published retrospective studies, but many did not elaborate on the type of arrhythmias elicited, nor on the specific treatment regimens prescribed. This included a combination of antiviral, antibacterial, glucocorticoid therapy or human immunoglobulin therapy, in addition to supportive care ( Table 1 ). The types of arrhythmias, when specified across all studies included thirteen cases of ventricular arrhythmias -ventricular tachycardia (VT) and fibrillation (VF), twenty-three cases of atrial arrhythmias -atrial fibrillation (AF), atrial This article is protected by copyright. All rights reserved flutter and atrial tachycardia, five cases of brady-arrhythmias -atrioventricular (AV) block, sinus bradycardia and complete heart block, and 260 cases of LQTS (Tables 1,2) . Compared with non-ICU admissions, there was a larger proportion of arrhythmias found in ICU admissions in two studies (1.2-16.7% and 40-44% respectively). 13, 20 In comparison, Guo et al reported malignant VA in 5.9% of all patients and in 11.5% of patients with concurrent troponin elevation, suggesting arrhythmia occurs more commonly in this subset. 16 In addition to tachy-arrhythmias, sinus nodal disease and AV block have been described, requiring permanent pacemaker insertion ( This article is protected by copyright. All rights reserved Our results demonstrate significant morbidity and mortality associated with arrhythmias (Tables 1-3 ). Based on cumulative incidence of 6.9%, we project 690,000 of ten million people infected with SARS-CoV-2 would have developed an arrhythmia, making it more arrhythmogenic than SARS and MERS. Some literature hypothesizes this to be due to increased virus affinity for ACE-2 but overall the exact reason for this remains unknown. Due to poor reporting of arrhythmias, as exemplified by retraction of two major studies, 32,33 our findings are likely an underestimation of the absolute prevalence of arrhythmias in this cohort. We postulate this to be due to still rising numbers of infected patients and subsequent demands placed on health care systems. Performing an ECG may be overlooked if patients lack symptoms suggestive of arrhythmia, in an attempt to reduce transmission and preserve scarce personal-protective equipment (PPE). evidence for conventional anti-arrhythmic agents is limited. Using AF as an example, patients were treated successfully with cardioversion or diltiazem. Amiodarone was avoided due to its QT-prolongation properties, particularly with concomitant use of other QT-prolonging agents. Beta-blockers were avoided due to risk of bronchospasm, especially in light of pneumonia or ARDS. Another concern is increased risk of thromboembolic events associated with SARS-CoV-2, and perhaps anticoagulation should be used irrespective of yearly stroke risk. 27, 34 There are no large trials addressing arrhythmia management in the setting of SARS-CoV-2 infection. Hence these decisions are made after assessment of risk and benefit on a case-by-case basis. Based on our calculated incidence of DI-LQTS, more than 1 million of the currently infected SARS-CoV-2 patients are at an increased risk of TdP. Treatment is aimed at targeting each of the pathways implicated in arrhythmia formation ( Figure 1 ). This is complicated as there is conflicting evidence regarding efficacy of HCQ, CQ and AZ as This article is protected by copyright. All rights reserved SARS-CoV-2 viral load reducing therapy. Whilst one series of six patients found reductions in viral load with AZ and HCQ, with low rates of adverse events, 35 their cohort lacked critically ill patients with comorbidities and multi-organ failure. In severe disease, another group found no evidence of clinical benefit with combination therapy. 18 Moreover, combination antimalarial and AZ therapy is associated with high rates of SARS-CoV-2 is more virulent than other coronaviruses due to its unique S-protein and higher affinity for ACE2, explaining its pro-arrhythmogenic potential. Comorbidities such as inherited arrhythmia, polypharmacy, cardiomyopathy, ischaemic heart disease and renal failure result in a lack of "repolarisation reserve", which predispose patients to developing LQTS. 38 Similarly, these are the same risk factors for severe respiratory compromise in SARS-CoV-2 infection, which are also the target population for combination antimalarial and AZ therapy. 38 The pharmacokinetics and pharmacodynamics of antimalarial therapy in SARS-CoV-2 infection also increases susceptibility to LQTS. The mechanism is not fully understood but thought to occur from inhibition of potassium repolarising currents. 39 This article is protected by copyright. All rights reserved Although combination therapy may be of benefit in inducing viral suppression, it seems safer to employ a monotherapy treatment strategy to reduce the risk of DI-LQTS and potential sequelae. This decision will be less difficult after RCTs such as RECOVERY (Table 5) . Finally, the lack of "repolarisation reserve" is of great concern particularly if genes such as p. This article is protected by copyright. All rights reserved The majority of the data extracted was from retrospective studies and case series. Most were not designed to primarily assess the incidence or treatment of arrhythmias in SARS-CoV-2 infection. Our search strategy was broad to include all agents trialled for treatment of SARS-CoV-2 infection, however all but one paper included the antiviral oseltamivir (Table 3) . Despite the arrhythmogenic properties of lopinavir and ritonavir, there were no studies within our search assessing DI-LQTS or arrhythmias secondary to these agents. All authors were involved in the interpretation of the data and edited the manuscript. Critical revision and final approval of the article was by RM and TT. The authors received no financial support for publication of this article. The authors report no relationships that could be construed as a conflict of interest This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved Retrospective cohort study Cleavage of viral S protein via an enzyme TMPRSS2 results in fusion of viral and host membrane leading to entry of virus into host cytoplasm. Direct infiltration of myocytes ensues which has been established in 35% of SARS-CoV patients. 1, 3, 47 Due to the genomic similarity between SARS-CoV and SARS-CoV-2, direct invasion by SARS-CoV-2 may also occur. Indirect myocardial injury results from systemic inflammatory response syndrome (SIRS). The sum of microvascular and macrovascular dysfunction, increased thrombogenicity, acidosis and hypoxia as well as the imbalance of T-helper 1 and 2 responses, leads to an intense release of cytokines and chemokines, particularly interleukin 1 (IL-1), interleukin 6 (IL-6) and tumour necrosis factor-alpha (TNF-). The heightened catecholaminergic response amplifies this process. In fact, hyper-inflammation due to high levels of IL-6 results in hERG potassium channel blockade and QT prolongation, facilitating formation of unstable arrhythmias. 47 Traditional cardiovascular risk factors such as type II diabetes mellitus, hypertension and hypercholesterolaemia, as well as comorbidities such as ischaemic heart disease and chronic renal failure also contribute to arrhythmia formation by altering cardiac structure and also responsible for clinically severe disease 12,13 Another potential contributor for arrhythmia formation in the setting of COVID-19 is the common SCN5A-encoded Nav1.5 sodium channel variant p.Ser1103Tyr-SCN5A which results in a lack of "repolarisation reserve". Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, metaregression), if done, indicating which were pre-specified. This article is protected by copyright. All rights reserved Describe the graphical and tabular methods used to present the effects (e.g., tables, forest plots, harvest plots). Specify key study characteristics (e.g., study design, risk of bias) used to order the studies, in the text and any tables or graphs, clearly referencing the studies included tachycardia" OR "ventricular fibrillation" OR AF OR SVT OR AVNRT OR VT OR VF OR "sinus node disease" OR "escape rhythm" OR "AV node conduction disease" OR "complete heart block" OR "Mobitz type 1" OR "Mobitz type 2" OR "long QT syndrome" OR LQTS OR "Newonset atrial fibrillation" OR "Auricular Fibrillation" OR "Paroxysmal Atrial Fibrillation" OR "Persistent Atrial Fibrillation" OR "Cardiac arrhythmia" OR "New-onset auricular Fibrillation" Consequence "Haemodynamic compromise" OR "haemodynamic instability" OR "sudden cardiac death*" OR SCD OR cardioversion* OR "early intervention*" OR "Medical intervention*" OR "Sudden arrest" OR "Sudden cardiac arrest" This article is protected by copyright. All rights reserved COVID-19: immunology and treatment options COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment Improving the Reporting Quality of Nonrandomized Evaluations of Behavioral and Public Health Interventions: The TREND Statement statement: extension checklist for reporting within person randomised trials JBI Manual for Evidence Synthesis -JBI Manual for Evidence Synthesis -JBI GLOBAL WIKI Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial Accepted Article This article is protected by copyright. All rights reserved 12 Clinical characteristics of coronavirus disease 2019 in China Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia QT interval prolongation and torsade De pointes in patients with COVID-19 treated with Hydroxychloroquine/azithromycin Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Cardiovascular complications of severe acute respiratory syndrome Clinical features and outcomes of 221 patients with COVID-19 in Wuhan Chloroquine-induced QTc prolongation in COVID-19 patients Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study) Coronavirus Coronavirus OR Covid19 OR Covid-19 OR SARS-CoV-2 OR infection OR "Coronavirus Infect*" OR MERS-CoV OR Arrhythmia Arrhythmia OR "sinus tachycardia" OR tachyarrhythmia OR "pathological arrhythmia" OR "atrial fibrillation" OR "atrial flutter" OR "atrial tachycardia" OR "supraventricular tachycardia" OR "ventricular FAERS CI= confidence interval, FAERS = FDA Adverse Event Reporting System ACE-2 = angiotensin-converting enzyme 2, S-protein = Spike protein, TMPRSS2= enzyme transmembrane protease serine 2, RNA = Ribonucleic acid, hERG = human ether-a-go-go related gene, QTc = corrected QT, p.Ser1103Tyr-SCN5A = SCN5Aencoded Nav1.5 sodium channel variant This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved Was the patient's history clearly described and presented as a timeline?3. Was the current clinical condition of the patient onWere diagnostic tests or assessment methods and the results clearly described?Was the intervention(s) or treatment procedure(s)Were adverse events (harms) or unanticipated This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved